B cell response to tumor antigens is associated with depletion of B progenitors in murine colocarcinoma

Surgery

Volumn 135, Issue 3, 2004, Pages 313-318

  Kirman, Irena ^a,b   Huang, Emina H ^a   Whelan, Richard L ^a  

^a Columbia University ^*  (United States)

^b BB1716 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ARTICLE; B LYMPHOBLAST; CANCER CELL CULTURE; CELL MATURATION; COLON CARCINOMA; CONTROLLED STUDY; EXPERIMENTAL MODEL; FLOW CYTOMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; WESTERN BLOTTING;

EID: 1542290090     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2003.09.002     Document Type: Article

References (24)

1. Ura Y, Ochi Y, Hamazu M, Ishida M, Nakajima K, Watanabe T. Studies on circulating antibody against carcinoembryonic antigen (CEA) and CEA-like antigen in cancer patients. Cancer Lett 1985;25:283-95.
2. Hurwitz E, Klapper LN, Wilchek M, Yarden Y, Sela M. Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies. Cancer Immunol Immunother 2000;49:226-34.
3. zum Buschenfelde CM, Hermann C, Schmidt B, Peschel C, Bernhard H. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 2002;62:2244-7.
4. Scanlan MJ, Welt S, Gordon CM, Chen YT, Gure AO, Stockert E, et al. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002;62:4041-7.
5. Lian ZX, Kita H, Okada T, Hsu T, Shultz LD, Dorshkind K, et al. Increased frequency of pre-pro B cells in the bone marrow of New Zealand Black (NZB) mice: implications for a developmental block in B cell differentiation. Dev Immunol 2002;9:35-45.
6. Chen C, Nagy Z, Radic MZ, Hardy RR, Husza D, Camper SA, et al. The site and stage of anti-DNA B cell deletion. Nature 1995;373:252-5.
7. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 1991; 173:1213-25.
8. Allman D, Li J, Hardy RR. Commitment to the B lymphoid lineage occurs before DH-JH recombination. J Exp Med 1999;189:735-40.
9. Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol 2001;19:595-621.
10. Bireland ML, Monroe JG. Biochemistry of antigen receptor signaling in mature and developing B lymphocytes. Crit Rev Immunol 1997;17:353-85.
11. Kirman I, Zhao K, Wang Y, Szabo P, Telford W, Weksler ME. Increased apoptosis of bone marrow pre-B cells in old mice associated with their low number. Int Immunol 1998;10: 1385-92.
12. Fulop G, Lee MY, Rosse C. A granulocytosis-inducing tumor inhibits the production of B lymphocytes in murine bone marrow. J Immunol 1985;135:4266-72.
13. Shendrik I, Kirman I, Trakht I, Orazi A. Bone marrow involved by metastatic breast cancer has a decreased percentage of B cell precursors [abstract]. Mod Pathol 2000;13:201A.
14. Lee MY, Fevold KL, Dorshkind K, Fukunaga R, Nagata S, Rosse C. In vivo and in vitro suppression of primary B lymphocytopoiesis by tumor-derived and recombinant granulocyte colony-stimulating factor. Blood 1993;82: 2062-8.
15. Kee BL, Cumano A, Iscove NN, Paige CJ. Stromal cell independent growth of bipotent B cell-macrophage precursors from murine fetal liver. Int Immunol 1994;6:401-7.
16. Ray RJ, Paige CJ, Furlonger C, Lyman SD, Rottapel R. Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Eur J Immunol 1996;26:1504-10.
17. Wei C, Zeff R, Goldschneider I. Murine pro-B cells require IL-7 and its receptor complex to up-regulate IL-7R alpha, terminal deoxynucleotidyltransferase, and c mu expression. J Immunol 2000;164:1961-70.
18. Hartley SB, Cooke MP, Fulcher DA, Harris AW, Cory S, Basten A, et al. Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell 1993;72:325-35.
19. Nossal GJ. Negative selection of lymphocytes. Cell 1994;76:229-39.
20. Pelanda R, Schwers S, Sonoda E, Torres RM, Nemazee D, Rajewsky K. Receptor editing in a transgenic mouse model: site, efficiency, and role in B cell tolerance and antibody diversification. Immunity 1997;7:765-75.
21. Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998;76:652-8.
22. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
23. Roovers RC, van der Linden E, Zulema H, de Bruine A, Arends JW, Hoogenboom HR. Evidence for a bias toward intracellular antigens in the local anti-tumor immune response of a colorectal cancer patient revealed by phage display. Int J Cancer 2001;93:832-40.
24. Somers VA, Brandwijk RJ, Joosten B, Moerkerk PT, Arends JW, Menheere P, et al. A panel of candidate tumor antigens in colorectal cancer revealed by the serological selection of a phage displayed cDNA expression library. J Immunol 2002;169:2772-80.